Y-27632 Dihydrochloride: Potent, Selective ROCK Inhibitor for Cytoskeletal and Stem Cell Research

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor with high selectivity for Rho-associated protein kinases ROCK1 and ROCK2, exhibiting an IC₅₀ of 140 nM for ROCK1 and a K_i of 300 nM for ROCK2 under in vitro conditions (APExBIO). By targeting the catalytic domain, Y-27632 effectively disrupts Rho-mediated stress fiber formation, cell cycle progression, and cytokinesis in mammalian cells (Guo et al., 2025). Its solubility and storage characteristics make it suitable for diverse experimental workflows. Peer-reviewed evidence confirms its use in modulating stem cell fate, tumor invasion, and cellular cytoskeleton organization. Y-27632 dihydrochloride (A3008, APExBIO) is widely adopted in cancer biology, regenerative medicine, and translational research.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases activated downstream of the small GTPase RhoA. These kinases regulate actin cytoskeleton dynamics, cell shape, migration, proliferation, and apoptosis. Dysregulation of ROCK signaling is implicated in cancer cell invasion, metastasis, stem cell differentiation, and tissue regeneration (Guo et al., 2025). Targeted inhibition of ROCK1/2 enables precise dissection of Rho/ROCK signaling pathways in cell and molecular biology. Y-27632 dihydrochloride provides a chemical tool for functional studies of cytoskeletal remodeling, stem cell viability, and tumor progression.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a reversible, ATP-competitive inhibitor that binds to the catalytic domains of ROCK1 and ROCK2. It suppresses ROCK kinase activity with an IC₅₀ of 140 nM (ROCK1) and a K_i of 300 nM (ROCK2) under in vitro conditions (APExBIO). This selectivity is over 200-fold greater compared to non-ROCK kinases such as PKC, PKA, MLCK, and PAK.

• Inhibition of ROCK prevents phosphorylation of downstream effectors, including myosin light chain (MLC) and LIM kinase, disrupting actin stress fiber assembly.
• Y-27632 suppresses Rho-mediated cell contraction, migration, and invasion.
• In stem cells, Y-27632 modulates cell cycle progression and enhances survival during dissociation and expansion.

By modulating cytoskeletal tension and cell adhesion, Y-27632 also interferes with cytokinesis, leading to altered cell proliferation and fate decisions (Guo et al., 2025).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM in biochemical assays (APExBIO).
• Demonstrated >200-fold selectivity over PKC, PKA, MLCK, and PAK in kinase profiling (APExBIO).
• Prevents Rho-mediated stress fiber formation and cellular contraction in fibroblasts and epithelial models (Guo et al., 2025, DOI).
• Reduces proliferation of prostatic smooth muscle cells in a dose-dependent manner in vitro (APExBIO).
• Suppresses tumor invasion and metastasis in mouse xenograft models (Guo et al., 2025, DOI).
• Enhances viability of human pluripotent stem cells during single-cell passaging (Related article).

This article extends the mechanistic and translational context provided in "Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for ..." by benchmarking selectivity and in vivo evidence, and updates "Precision Targeting of Rho/ROCK Signaling: Y-27632 Dihydr..." by integrating peer-reviewed data from 2025 on stem cell and tumor models.

Applications, Limits & Misconceptions

Applications

• Dissection of the Rho/ROCK signaling pathway in cell motility and cytoskeletal studies.
• Enhancement of stem cell viability and expansion in culture, especially for human pluripotent stem cells.
• Suppression of tumor invasion and metastasis in preclinical cancer models.
• Modulation of cell cycle progression and cytokinesis in proliferation assays.

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; it is highly selective for ROCK1/2 and ineffective against PKC, PKA, or MLCK at concentrations ≤10 μM (APExBIO).
• It does not directly promote differentiation of stem cells; its principal effect is on survival and cytoskeletal remodeling.
• In vivo efficacy may be limited by pharmacokinetics and tissue penetration; not suitable for systemic clinical application without further modification.
• Long-term storage of solutions (especially in aqueous buffer) may reduce potency; prepare fresh aliquots when possible (APExBIO).
• High concentrations (>50 μM) can induce off-target effects and cytotoxicity.

Workflow Integration & Parameters

• Y-27632 dihydrochloride (A3008) is supplied as a solid and should be stored desiccated at ≤4°C.
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water; warming to 37°C or using an ultrasonic bath enhances dissolution (APExBIO).
• For cell culture, typical working concentrations range from 1–20 μM, depending on cell type and application.
• Stock solutions can be stored at –20°C for several months; avoid repeated freeze-thaw cycles.
• Recommended for use in cell proliferation assays, cytoskeletal remodeling studies, and in vitro tumor invasion models.

Conclusion & Outlook

Y-27632 dihydrochloride is a validated, highly selective ROCK1/2 inhibitor for cell-permeable modulation of the Rho/ROCK pathway in research settings. Its robust selectivity profile, solubility, and performance in both cell-based and animal models make it a standard tool in cancer biology, stem cell research, and cytoskeletal studies. APExBIO's A3008 kit offers consistency and reproducibility for demanding experimental workflows. Future research may extend its applications to organoid modeling and regenerative medicine, as suggested by recent advances (Guo et al., 2025).

For a comprehensive product specification and ordering, refer to the Y-27632 dihydrochloride product page.